$VRAL’s VGV-1 is in preclinical stages of development in the United States and in much later stages of development in other countries. Why the difference? Perhaps you have heard that HIV and AIDS in Africa is much more prevalent than anywhere else in the world!
The Dean says the bottom line is that demand is demand, especially when it comes to pharmaceuticals. With an increase of infectious diseases and numerous types of cancers over the past decade, there is an immediate need for the types of products Viral Genetics is working on.
In addition to optimizing its products, $VRAL has also been working to strengthen its corporate structure by recently eliminating the majority of its debt. Also, within the past month, $VRAL surged over 200% in speculation that its arsenal of HIV, cancer, and Lyme disease treatments will be a huge success.
The Dean is so enthusiastic about $VRAL because they have also recently established a patent for the first method of treating drug resistant cancers. Since many cancers are evolving to develop drug resistance, Viral Genetics’ approach differs from others because they are working to address these types of cancers.
Viral Genetics CEO Haig Keledjian has said that “Drug resistance, either acquired or inherent, is the leading cause of death in cancer.” Students, let me paint a picture for you. Cancer is a disease that kills “at least 6.2 million people worldwide annually.” Since $VRAL is working progressively on drug resistant cancers, The Dean is confident that the types of new therapies Viral Genetics is developing will make $VRAL stand out and rise above the rest. Spread the Word.
No comments:
Post a Comment